TB-500 Dosage Calculator

The presets in our calculator reflect the dosing parameters most frequently utilized in in vivo tissue healing, cellular motility, and neovascularization models.

• Low (2.5mg): Often utilized as a maintenance dosage or in baseline systemic models observing ongoing cellular repair, flexibility, and anti-inflammatory baseline support.[1]
• Mid (5.0mg): The standard median dosage in experimental literature, widely cited in acute protocols evaluating accelerated healing of muscle tears, ligament injuries, and dermal wound repair.[2]
• High (10.0mg): Typically reserved for severe trauma models, post-surgical cardiac tissue recovery simulations, or subjects with higher total body mass requiring a robust, systemic upregulation of actin-sequestering proteins.[3]
  

In experimental protocols, TB-500 is most commonly administered two times weekly during the acute injury phase. Because it operates via the upregulation of cellular actin and maintains a longer systemic duration of action than other local repair peptides (such as BPC-157), researchers frequently transition to a vastly reduced maintenance schedule (e.g., once weekly or bi-weekly) once initial macroscopic tissue repair is achieved.[2]

• Subcutaneous (SubQ): The benchmark route for systemic research. TB-500 possesses a low molecular weight and unique molecular structure that allows it to travel efficiently through the bloodstream to seek out and accumulate at localized areas of injury and inflammation.[1]
• Intramuscular (IM): Occasionally utilized to introduce the peptide adjacent to specific sites of muscular trauma, though systemic SubQ absorption is universally considered equally effective for widespread wound healing and angiogenesis.
  

TB-500 research generally follows acute to sub-acute timelines, focusing on the rapid activation of progenitor cells and blood vessel formation:

• Acute Repair Models: 4 to 6 weeks is the standard timeline for observing localized tissue healing, cardiovascular recovery, and a return to baseline structural integrity.[3]
• Maintenance Models: Extended observation phases often involve drastically reduced dosing frequencies solely to maintain baseline cellular motility and evaluate injury prevention over time.
  

While extensive in vitro and animal models demonstrate TB-500’s profound ability to upregulate actin, stimulate angiogenesis, and accelerate multi-tissue repair, large-scale, peer-reviewed human clinical trials are currently limited. TB-500 (Thymosin Beta-4) is not approved by the FDA for treating muscular injuries, cardiovascular conditions, or inflammatory disorders in humans. All data provided is strictly for educational context, and all compounds are restricted to Research Use Only (RUO).

1. Philp D, Goldstein AL, Kleinman HK. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113-115. https://pubmed.ncbi.nlm.nih.gov/15082067/
2. Treadwell T, Kleinman HK, Crockford D, Hardy MA, Guarnera GT, Goldstein AL. The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients. Ann N Y Acad Sci. 2012;1270(1):37-44. https://pubmed.ncbi.nlm.nih.gov/23046206/
3. Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182. https://pubmed.ncbi.nlm.nih.gov/17115049/